Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6JN3

Serine Beta-Lactamase KPC-2 in Complex with Dual MBL/SBL Inhibitor MS05

6JN3 の概要
エントリーDOI10.2210/pdb6jn3/pdb
分子名称Serine Beta-Lactamase KPC-2, [(1R)-1-[[(2S)-2-methyl-3-sulfanyl-propanoyl]amino]-2-phenyl-ethyl]boronic acid, DI(HYDROXYETHYL)ETHER, ... (5 entities in total)
機能のキーワードbeta-lactamase, serine-beta-lactamase kpc-2, kpc-2, carbapenemase, hydrolase
由来する生物種Klebsiella pneumoniae
タンパク質・核酸の鎖数4
化学式量合計114444.03
構造登録者
Li, G.-B.,Liu, S. (登録日: 2019-03-13, 公開日: 2019-07-17, 最終更新日: 2024-11-20)
主引用文献Wang, Y.L.,Liu, S.,Yu, Z.J.,Lei, Y.,Huang, M.Y.,Yan, Y.H.,Ma, Q.,Zheng, Y.,Deng, H.,Sun, Y.,Wu, C.,Yu, Y.,Chen, Q.,Wang, Z.,Wu, Y.,Li, G.B.
Structure-Based Development of (1-(3'-Mercaptopropanamido)methyl)boronic Acid Derived Broad-Spectrum, Dual-Action Inhibitors of Metallo- and Serine-beta-lactamases.
J.Med.Chem., 62:7160-7184, 2019
Cited by
PubMed Abstract: The emergence and spread of bacterial pathogens acquired metallo-β-lactamase (MBL) and serine-β-lactamase (SBL) medicated β-lactam resistance gives rise to an urgent need for the development of new dual-action MBL/SBL inhibitors. Application of a pharmacophore fusion strategy led to the identification of (2')-(1-(3'-mercapto-2'-methylpropanamido)methyl)boronic acid () as a new dual-action inhibitor, which manifests broad-spectrum inhibition to representative MBL/SBL enzymes, including the widespread VIM-2 and KPC-2. Guided by the VIM-2: and KPC-2: complex structures, further structural optimization yielded new, more potent dual-action inhibitors. Selectivity studies indicated that the inhibitors had no apparent inhibition to human angiotensin-converting enzyme-2 and showed selectivity across serine hydrolyases in and human HEK293T cells labeled by the activity-based probe TAMRA-FP. Moreover, the inhibitors displayed potentiation of meropenem efficacy against MBL- or SBL-positive clinical isolates without apparent cytotoxicity. This work will aid efforts to develop new types of clinically useful dual-action inhibitors targeting MBL/SBL enzymes.
PubMed: 31269398
DOI: 10.1021/acs.jmedchem.9b00735
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.216 Å)
構造検証レポート
Validation report summary of 6jn3
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon